5 research outputs found
Phase I study of subcutaneous allergen immunotherapy with Dermatophagoides pteronyssinus
Is Microarray Analysis Really Useful and Sufficient to Diagnose Nut Allergy in the Mediterranean Area?
Background: Component-based diagnosis on multiplex platforms is widely used in food allergy but its clinical performance has not been
evaluated in nut allergy.
Objective: To assess the diagnostic performance of a commercial protein microarray in the determination of specific IgE (sIgE) in peanut,
hazelnut, and walnut allergy.
Methods: sIgE was measured in 36 peanut-allergic, 36 hazelnut-allergic, and 44 walnut-allergic patients by ISAC 112, and subsequently,
sIgE against available components was determined by ImmunoCAP in patients with negative ISAC results. ImmunoCAP was also used to
measure sIgE to Ara h 9, Cor a 8, and Jug r 3 in a subgroup of lipid transfer protein (LTP)-sensitized nut-allergic patients (positive skin prick
test to LTP-enriched extract). sIgE levels by ImmunoCAP were compared with ISAC ranges.
Results: Most peanut-, hazelnut-, and walnut-allergic patients were sensitized to the corresponding nut LTP (Ara h 9, 66.7%; Cor a 8,
80.5%; Jug r 3, 84% respectively). However, ISAC did not detect sIgE in 33.3% of peanut-allergic patients, 13.9% of hazelnut-allergic
patients, or 13.6% of walnut-allergic patients. sIgE determination by ImmunoCAP detected sensitization to Ara h 9, Cor a 8, and Jug r 3 in,
respectively, 61.5% of peanut-allergic patients, 60% of hazelnut-allergic patients, and 88.3% of walnut-allergic patients with negative
ISAC results. In the subgroup of peach LTPâsensitized patients, Ara h 9 sIgE was detected in more cases by ImmunoCAP than by ISAC
(94.4% vs 72.2%, P<.05). Similar rates of Cor a 8 and Jug r 3 sensitization were detected by both techniques.
Conclusions: The diagnostic performance of ISAC was adequate for hazelnut and walnut allergy but not for peanut allergy. sIgE sensitivity
against Ara h 9 in ISAC needs to be improved.IntroducciĂłn: La utilidad clĂnica del diagnĂłstico por componentes no ha sido evaluada en el estudio de la alergia a frutos secos (FS).
Objetivo: Evaluar la capacidad diagnĂłstica de una micromatriz comercial de proteĂnas alergĂ©nicas en la alergia a cacahuete, avellana y nuez.
Métodos: Se determinó la sIgE en pacientes alérgicos a FS mediante la micromatriz ISAC 112, e ImmunoCAP en los pacientes con sIgE
negativa frente a los componentes de ISAC. AdemĂĄs, se realizĂł ImmunoCAP frente a Ara h 9, Cor a 8 y Jug r 3 en un subgrupo de pacientes
sensibilizados a LTP. La sIgE detectada por ImmunoCAP fue comparada con los rangos de ISAC.
Resultados: La mayorĂa de los alĂ©rgicos a cacahuete (66,7%), avellana (80,5%) y nuez (84%) estaba sensibilizados a su LTP. Sin embargo,
no se detectó sIgE frente a los componentes de ISAC en el 33,3% de alérgicos a cacahuete, 13,9% de alérgicos a avellana y 13,6% de
los alérgicos a nuez. El ImmunoCAP permitió detectar sIgE a Ara h 9 en 61,5%, Cor a 8 en 60% y Jug r 3 en 83,3% de los ISAC negativo.
En el subgrupo LTP, ImmunoCAP (94,4%) fue superior a ISAC (72,2%) en la detecciĂłn de sIgE a Ara h 9 (p<0,05). La sIgE frente a Cor a 8
y Jug r 3 fue detectada de forma similar por ambas técnicas.
Conclusiones: La micromatriz ISAC es adecuada para el diagnĂłstico de alergia a avellana y nuez. La sensibilidad del componente Ara h 9
de ISAC debe ser mejorada
The burden of mild asthma: Clinical burden and healthcare resource utilisation in the NOVELTY study
Background: Patients with mild asthma represent a substantial proportion of the population with asthma, yet there are limited data on their true burden of disease. We aimed to describe the clinical and healthcare resource utilisation (HCRU) burden of physician-assessed mild asthma.Methods: Patients with mild asthma were included from the NOVEL observational longiTudinal studY (NOVELTY; NCT02760329), a global, 3-year, real-world prospective study of patients with asthma and/or chronic obstructive pulmonary disease from community practice (specialised and primary care). Diagnosis and severity were based on physician discretion. Clinical burden included physician-reported exacerbations and patient-reported measures. HCRU included inpatient and outpatient visits.Results: Overall, 2004 patients with mild asthma were included; 22.8% experienced â„1 exacerbation in the previous 12 months, of whom 72.3% experienced â„1 severe exacerbation. Of 625 exacerbations reported, 48.0% lasted >1 week, 27.7% were preceded by symptomatic worsening lasting >3 days, and 50.1% required oral corticosteroid treatment. Health status was moderately impacted (St George's Respiratory Questionnaire score: 23.5 [standard deviation ± 17.9]). At baseline, 29.7% of patients had asthma symptoms that were not well controlled or very poorly controlled (Asthma Control Test score <20), increasing to 55.6% for those with â„2 exacerbations in the previous year. In terms of HCRU, at least one unscheduled ambulatory visit for exacerbations was required by 9.5% of patients, including 9.2% requiring â„1 emergency department visit and 1.1% requiring â„1 hospital admission.Conclusions: In this global sample representing community practice, a significant proportion of patients with physician-assessed mild asthma had considerable clinical burden and HCRU
Treatable traits in the NOVELTY study
CorrigendumVolume 27, Issue 12, Respirology, pages: 1095-1095. First Published online: November 6, 2022 10.1111/resp.14406International audienceAsthma and chronic obstructive pulmonary disease (COPD) are two prevalent and complex diseases that require personalized management. Although a strategy based on treatable traits (TTs) has been proposed, the prevalence and relationship of TTs to the diagnostic label and disease severity established by the attending physician in a real-world setting are unknown. We assessed how the presence/absence of specific TTs relate to the diagnosis and severity of 'asthma', 'COPD' or 'asthmaâ+âCOPD'